AIGENDRUG Co., Ltd.

AIGENDRUG Co., Ltd. (Korean: 아이겐드럭) is a South Korean artificial intelligence drug discovery company headquartered in Seoul. The company positions itself as a global AI-driven drug development firm whose mission is to broaden drug discovery research and contribute to human health. Its core asset is DrugVLAB, an AI drug discovery platform that the company says is revolutionizing the pharmaceutical development paradigm by efficiently identifying optimal drug candidates and minimizing the costs and risks associated with failure in preclinical and clinical stages. AIGENDRUG's technology is organized around three complementary modeling domains. In the chemical space, the company stratifies compound space using hierarchical structural properties from in-house data, considering both structural similarity and diversity to identify optimized lead compounds similar to drugs in development while generating new compounds with structural diversity and functional similarity. In the genetic space, it integrates gene expression levels, epigenetic regulation and protein levels from multi-omics data to elucidate mechanisms of action and predict drug efficacy, ADME and toxicity, and to stratify patients based on biomarkers. In the disease space, it models diseases using clinical data to support drug repositioning and drug combination development through synergy analysis. The company commercializes this technology through a portfolio of offerings that includes standalone tools, pre-built packages and customized packages, and it maintains a publications record alongside a newsroom with press releases and announcements. AIGENDRUG has been recognized by Korean government and industry programs: in 2024 it won first prize (Minister of Health and Welfare Award) at JUMP AI 2024, an AI new drug development competition, and secured angel investment in December 2024. In 2025 it was selected as the lead organization for the AI Drug Development End-to-End Technology Project by the Ministry of Trade, Industry and Energy, received the 2025 Korea Good Company Award (Good R&D Award), and participated in BioUSA 2025. It also participated in BioUSA 2024 and was selected for government R&D grants including the Global Physician-Scientist Training Program (AI-based). AIGENDRUG describes itself as a collaborative company committed to social responsibility and to an excellent working environment where the company and its employees grow together. Its stated value proposition is improving the efficiency and success rates in drug discovery with world-class technology to overcome diseases, creating customized value for clients. The company remains privately held and is not known to be listed on a public exchange.

AIGENDRUG Co., Ltd. is a South Korean AI drug discovery company based in Seoul. The company's public history, as presented on its official website, is recent and centered on the development and recognition of its DrugVLAB platform. AIGENDRUG states that it is revolutionizing the pharmaceutical development paradigm through DrugVLAB, an AI drug discovery platform that efficiently identifies optimal drug candidates and minimizes the costs and risks associated with failure in preclinical and clinical stages. The company's technology rests on three modeling domains. Its chemical space work stratifies compound space using hierarchical structural properties from in-house data, considering both structural similarity and diversity to identify optimized lead compounds similar to drugs in development while generating new compounds with structural diversity and functional similarity. Its genetic space work integrates gene expression levels, epigenetic regulation and protein levels from multi-omics data to elucidate mechanisms of action, predict drug efficacy, ADME and toxicity, and stratify patients based on biomarkers. Its disease space work models diseases using clinical data to support drug repositioning and drug combination development through synergy analysis. AIGENDRUG commercializes its platform through standalone tools, pre-built packages and customized packages, and maintains a publications record and a newsroom with press releases and announcements. The company's documented milestones begin in 2024. In April 2024 it was selected for government R&D grants under the Global Physician-Scientist Training Program (AI-based). In June 2024 it participated in BioUSA 2024. In October 2024 it won first prize, the Minister of Health and Welfare Award, at JUMP AI 2024, an AI new drug development competition. In December 2024 it secured angel investment. In 2025 the company continued to gain recognition. In June 2025 it was selected as the lead organization for the AI Drug Development End-to-End Technology Project by the Ministry of Trade, Industry and Energy, and it participated in BioUSA 2025. In August 2025 it was awarded the 2025 Korea Good Company Award (Good R&D Award). AIGENDRUG describes its mission as broadening drug discovery research to contribute to human health, and its values as improving the efficiency and success rates in drug discovery with world-class technology to overcome diseases, creating customized value for clients as a global AI-driven drug development company, operating as a collaborative company committed to social responsibility, and maintaining an excellent working environment where the company and its employees grow together. The company is privately held and headquartered in Seoul, South Korea.

• Selected for government R&D grants (Global Physician-Scientist Training Program – AI-based)

• Participated in BioUSA 2024

• Won 1st Prize (Minister of Health and Welfare Award) at JUMP AI 2024 (AI New Drug Development Competition)

• Secured Angel Investment

• Selected as lead organization for the AI Drug Development End-to-End Technology Project by the Ministry of Trade, Industry and Energy

• Participated in BioUSA 2025

• Awarded the 2025 Korea Good Company Award (Good R&D Award)

Global AI-driven drug development company creating customized value for clients, improving efficiency and success rates in drug discovery.

• DrugVLAB™

  AI drug discovery platform integrating multi-omics and compound data to identify optimal drug candidates.

• Standalone Tools

  Individual software tools offered by AIGENDRUG.

• Pre-built Packages

  Packaged offerings for drug discovery workflows.

• Customized Packages

  Tailored packages for client-specific drug discovery needs.

1. 1아이겐드럭 - 홈페이지aigendrug.com
2. 2아이겐드럭 - About Usaigendrug.com
3. 3AIGENDRUG Co., Ltd. (South Korea) - Wikidatawikidata.org